Biotinylated Human VEGF165, epitope tag free, ultra sensitivity (primary amine labeling)

Source : 

MABSol® Biotinylated Human VEGF165, epitope tag free, primary amine labeling (VE5-H8210) is expressed from human HEK293 cells. It contains AA Ala 27 - Arg 191 (Accession # NP_001165097). It is the biotinylated form of ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (VE5-H4210).

 

Molecule : VEGF165

 

Synonyms : RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

 

Format : Powder

 

Category : MABSol® Biotin Labeled Proteins

 

Accession : NP_001165097

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 19.2 kDa

 

Characteristics :

This protein carries no "tag". The protein has a calculated MW of 19.2 kDa. As a result of glycosylation, the protein migrates as 25-30 kDa (monomer) under reducing (R) condition, and 43-50 kDa under non-reducing (NR) condition (SDS-PAGE).

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : PBS, pH7.4

 

Description :

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

 

References :

(1) Takahashi, H. and Shibuya, M., 2005, Clin Sci (Lond) 109, 227-41.
(2) Neufeld, G. et al., 1999, FASEB J 13, 9-22.
(3) Robinson, C.J. and Stringer, S.E., 2001, J Cell Sci 114, 853-65.